AI Article Synopsis
- FPR2 plays a crucial role in managing inflammation during heart injuries, affecting both the start and end phases of the inflammatory response.
- Uncontrolled inflammation can worsen heart conditions, leading to poor healing and increased risk of heart failure.
- The review highlights new findings about FPR2 in heart disease, discusses the potential benefits of using FPR2 agonists in treatment, and mentions ongoing clinical evaluations of these drugs.
Article Abstract
Formyl peptide receptor type 2 (FPR2) regulates the initiation and resolution phases of the inflammatory response. In the setting of heart injury and disease, dysregulated inflammation can potentiate maladaptive healing and pathological remodeling of the heart leading to cardiac dysfunction and failure. The potential to regulate and resolve adverse inflammation is postulated to improve outcome in the setting of heart disease. This review covers emerging concepts on the role of FPR2 in heart disease and strategies to activate pro-resolution processes to limit disease progression. We summarize key preclinical studies that support use of FPR2 agonists in heart disease. Finally, we briefly discuss the status of FPR2 agonists under evaluation in the clinic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.smim.2022.101602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!